Schade, Dennis

Differentiation of cardiomyocytes and generation of human engineered heart tissue

Breckwoldt, K., Letuffe-Brenière, D., Mannhardt, I., Schulze, T., Ulmer, B., Werner, T., Benzin, A., Klampe, B., Reinsch, M. C., Laufer, S., et al. (2017) · Nature Protocols

Pluripotent Stem Cells ResearchTissue Engineering and Regenerative Medicine

Cited by 272

Cell Permeable Stapled Peptide Inhibitor of Wnt Signaling that Targets β-Catenin Protein-Protein Interactions

Dietrich, L., Rathmer, B., Ewan, K., Bange, T., Heinrichs, S., Dale, T. C., Schade, D., & Grossmann, T. N. (2017) · Cell Chemical Biology

Chemical Synthesis and AnalysisWnt/β-catenin signaling in development and cancer

Cited by 126

Reduction of N ω-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC)

Kotthaus, J., Wahl, B., Havemeyer, A., Kotthaus, J., Schade, D., Garbe-Schönberg, D., Mendel, R., Bittner, F., & Clement, B. (2011) · Biochemical Journal

Nitric Oxide and Endothelin EffectsMitochondrial Function and Pathology

Cited by 88

A protein tertiary structure mimetic modulator of the Hippo signalling pathway

Adihou, H., Gopalakrishnan, R., Förster, T., Guéret, S. M., Gasper, R., Geschwindner, S., Carrillo García, C., Karatas, H., Pobbati, A. V., Vazquez‐Chantada, M., et al. (2020) · Nature Communications

Hippo pathway signaling and YAP/TAZChemical Synthesis and Analysis

Cited by 58

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., et al. (2024) · Cancers

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 14